secwatch.observer — SEC 8-K summary
======================================

Issuer:     BiomX Inc. (PHGE)
CIK:        0001739174
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001213900-25-025820
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

BiomX Announces Positive Phase 2 Results for BX211 in Diabetic Foot Osteomyelitis
--------------------------------------------------------------------------------

- BX211 showed statistically significant ulcer size reduction (PAR) at week 12 (p=0.046) and week 13 (p=0.052) vs placebo.
- BX211 reduced ulcer depth (p=0.048) and limited ulcer area expansion (p=0.017) compared to placebo.
- Phase 2 trial enrolled 41 patients (26 BX211, 15 placebo) with DFO associated with S. aureus; BX211 safe and well-tolerated.
- BiomX plans Phase 2/3 trial pending FDA feedback; KOL event scheduled April 3, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739174/000121390025025820/0001213900-25-025820-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739174/000121390025025820/ea0236313-8k_biomx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-025820

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer